Apyx Medical Reports Q3 2026 Revenue Growth Driven by Surgical Aesthetics Segment
Apyx Medical (APYX) reported third-quarter 2026 revenue of $14.0 million, a 9% increase year-over-year. This growth was primarily fueled by the Surgical Aesthetics segment, which reached $13.0 million due to strong domestic sales of the AYON system and increased international demand for Renuvion generators, particularly in South Korea. Despite the revenue growth, the company reported a net loss of $1.8 million ($0.04 per share). However, management highlighted an improvement in Adjusted EBITDA to $0.4 million compared to a loss in the prior year. The company also achieved positive cumulative trailing 12-month EBITDA, signaling progress toward sustained profitability. Looking ahead, Apyx reaffirmed its full-year revenue guidance of $59 million to $60 million while lowering its operating expense guidance to between $41.0 million and $42.5 million. The company aims to capitalize on the growing patient pipeline created by weight-loss medications and continued international expansion.
Tickers: $APYX
Topics: financial performance net loss revenue growth surgical aesthetics